Immutep (IMMP) Receives a New Rating from a Top Analyst
Maxim Group analyst Jason McCarthy assigned a Buy rating to Immutep (IMMP) yesterday and set a price target of $8.00. The company’s shares closed last Friday at $3.14.
According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 51.8% and a 55.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Lineage Cell Therapeutics.
Immutep has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.95 and a one-year low of $0.53. Currently, Immutep has an average volume of 2.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.